NCT06388187CompletedPhase 3
A research study to see how well different doses of CagriSema help people with excess body weight lose weight
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) once-weekly in participants with overweight or obesity
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Mar 2026
Brief summary (registry, in English)
To confirm superiority on body weight reduction of CagriSema 00 mg/00 mg and CagriSema 00 mg/00 mg versus placebo as an adjunct to reduced-calorie diet and increased physical activity in participants with overweight or obesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 11 Mar 2024
- Start date
- 5 Sept 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- EU CT number
- 2023-509273-24-00
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 100
- 8 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of type 1 or type 2 diabetes
Lab values
- HbA1c ≥6.5% (48 mmol/mol) as measured by the central laboratory at screening
Who the study is looking for
- History of at least one self-reported unsuccessful dietary effort to lose body weight
- BMI ≥30.0 kg/m2a or b) BMI ≥27.0 kg/m2a with the presence of at least one obesity-related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| InnoDiab Forschung Gmbh Coordinator of this site? Confirm its status | Essen | Germany | Completed |
| Wendisch/Dahl Hamburg Coordinator of this site? Confirm its status | Hamburg | Germany | Completed |
| Ambenet GmbH Das Ambulante Behandlungsnetz Coordinator of this site? Confirm its status | Leipzig | Germany | Completed |
| Institut fuer Diabetesforschung Muenster GmbH Coordinator of this site? Confirm its status | Muenster | Germany | Completed |
| KliFoCenter GmbH Coordinator of this site? Confirm its status | Witten | Germany | Completed |
| Hospices Civils de Lyon Coordinator of this site? Confirm its status | Pierre-Bénite | France | Completed |
| Centre Hospitalier Universitaire de Nantes Coordinator of this site? Confirm its status | Saint-Herblain | France | Completed |
| Centre Hospitalier Universitaire De Toulouse Coordinator of this site? Confirm its status | Toulouse Cedex 9 | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.